Teckman Jeffrey H, Rosenthal Philip, Abel Robert, Bass Lee M, Michail Sonia, Murray Karen F, Rudnick David A, Thomas Daniel W, Spino Cathie, Arnon Ronen, Hertel Paula M, Heubi James, Kamath Binita M, Karnsakul Wikrom, Loomes Kathleen M, Magee John C, Molleston Jean P, Romero Rene, Shneider Benjamin L, Sherker Averell H, Sokol Ronald J
*Pediatrics and Biochemistry, Saint Louis University, Cardinal Glennon Children's Medical Center, St Louis, MO †Pediatrics and Surgery, University of California San Francisco, San Francisco ‡Biostatistics, University of Michigan, Ann Arbor, MI §Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL ||Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los Angeles, CA ¶Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA #Pediatrics, Washington University, St Louis, MO **Pediatrics, Mount Sinai School of Medicine, New York, NY ††Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston ‡‡Pediatric Gastroenterology and Hepatology, Children's Hospital Medical Center, Cincinnati, OH §§Pediatric Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, Toronto, Canada ||||Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD ¶¶Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA ##Surgery, University of Michigan School of Medicine, Ann Arbor ***Pediatric Gastroenterology, Hepatology and Nutrition, James Whitcomb Riley Hospital for Children, Indianapolis, IN †††Pediatrics, Emory University, Children's Healthcare Atlanta, Atlanta, GA ‡‡‡Pediatrics, University of Pittsburgh, Pittsburgh, PA §§§National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Baltimore, MD ||||||Pediatric Gastroenterology, University of Colorado, Children's Hospital Colorado, Aurora.
J Pediatr Gastroenterol Nutr. 2015 Jul;61(1):94-101. doi: 10.1097/MPG.0000000000000753.
α-1-Antitrypsin (A1AT) deficiency is a common genetic disease with an unpredictable and highly variable course. The Childhood Liver Disease Research and Education Network is a National Institutes of Health, multicenter, longitudinal consortium studying pediatric liver diseases, with the objective of prospectively defining natural history and identifying disease modifiers.
Longitudinal, cohort study of A1AT patients' birth through 25 years diagnosed as having liver disease, type PIZZ or PISZ. Medical history, physical examination, laboratory, imaging, and standardized survey tool data were collected during the provision of standard of care.
In the present report of the cohort at baseline, 269 subjects were enrolled between November 2008 and October 2012 (208 with their native livers and 61 postliver transplant). Subjects with mild disease (native livers and no portal hypertension [PHT]) compared to severe disease (with PHT or postliver transplant) were not different in age at presentation. A total of 57% of subjects with mild disease and 76% with severe disease were jaundiced at presentation (P = 0.0024). A total of 29% of subjects with native livers had PHT, but age at diagnosis and growth were not different between the no-PHT and PHT groups (P > 0.05). Subjects with native livers and PHT were more likely to have elevated bilirubin, ALT, AST, INR, and GGTP than the no-PHT group (P << 0.001), but overlap was large. Chemistries alone could not identify PHT.
Many subjects with A1AT presenting with elevated liver tests and jaundice improve spontaneously. Subjects with PHT have few symptoms and normal growth. Longitudinal cohort follow-up will identify genetic and environmental disease modifiers.
α-1-抗胰蛋白酶(A1AT)缺乏症是一种常见的遗传性疾病,病程不可预测且高度可变。儿童肝病研究与教育网络是美国国立卫生研究院的一个多中心纵向联盟,致力于研究儿童肝病,目的是前瞻性地确定其自然病史并识别疾病修饰因子。
对诊断为患有肝病、PIZZ型或PISZ型的A1AT患者进行从出生到25岁的纵向队列研究。在提供标准治疗期间收集病史、体格检查、实验室检查、影像学检查和标准化调查工具数据。
在本队列研究的基线报告中,2008年11月至2012年10月期间共纳入269名受试者(208名保留自身肝脏,61名接受肝移植后)。与严重疾病(患有门静脉高压[PHT]或肝移植后)的受试者相比,轻度疾病(保留自身肝脏且无门静脉高压)的受试者就诊时年龄无差异。轻度疾病的受试者中有57%、严重疾病的受试者中有76%在就诊时出现黄疸(P = 0.0024)。保留自身肝脏的受试者中有29%患有门静脉高压,但无门静脉高压组和门静脉高压组在诊断时的年龄和生长情况无差异(P>0.05)。与无门静脉高压组相比,保留自身肝脏且患有门静脉高压的受试者更有可能出现胆红素、谷丙转氨酶、谷草转氨酶、国际标准化比值和γ-谷氨酰转肽酶升高(P << 0.001),但重叠范围较大。仅靠化学检查无法识别门静脉高压。
许多出现肝功能检查异常和黄疸的A1AT受试者会自发改善。患有门静脉高压的受试者症状较少且生长正常。纵向队列随访将识别遗传和环境疾病修饰因子。